SGTX — Sigilon Therapeutics Share News
0.000.00%
Last trade - 00:00- $56.50m
- $17.21m
- $12.94m
Sigilon rises after UK allows clinical trial of genetic disorder therapy
Brief: Sigilon Therapeutics Announces Acceptance Of Clinical Trial Application In The Uk For Sig-005 For The Treatment Of Mucopolysaccharidosis Type I
Sigilon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Sigilon Therapeutics Reports Second Quarter 2021 Financial Results
Brief: Sigilon Therapeutics Presents Preclinical Data At The 16th International Symposium On Mps And Related Diseases
Brief: Sigilon Therapeutics Names Ajay Rai As Senior Vice President, Head Of Business Development
U.S. STOCKS ON THE MOVE-Gap, Biogen, Levi Strauss, Didi
Sigilon Therapeutics dives after FDA puts blood disorder trial on hold
NASDAQ RESUMED AT 08:00 AM
Brief: Sigilon Therapeutics Announces Clinical Hold On Sig-001 Phase 1/2 Study In Hemophilia A
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM
Brief: Sigilon Therapeutics Says Glenn Reicin Delivered His Resignation As CFO And Treasurer, Effective June 14
Sigilon Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Sigilon Therapeutics Posts Quarterly Loss Per Share Of $0.60
Brief: Sigilon Therapeutics Reports Fourth Quarter And Full Year 2020 Financial Results And Business Highlights
Brief: Sigilon Therapeutics Receives Orphan Drug Designation For SIG-007 For Treatment Of Fabry Disease
U.S. STOCKS ON THE MOVE-AmerisourceBergen, ReneSola Ltd, Big Tech stocks
U.S. RESEARCH ROUNDUP- Aprea Therapeutics, Beyondspring, Cognizant Technology
Brief: Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I